SARS-CoV-2 inhibition and specific targeting of infected cells by VSV particles carrying the ACE2 receptor

Fabian Zech, Stefanie Weber, Hanna Dietenberger, Linyun Zhang, Sabrina Noettger, Meta Volčič, Tim Bergner, Clarissa Read, Konstantin M. J. Sparrer, Thomas F.e. Barth, Frank KirchhoffSignal 2023 · DOI · OpenAlex

Introduction

Despite the success of vaccines and antiviral agents, the ongoing evolution of SARS-CoV-2 variants poses a significant challenge to global health. Emerging variants often evade immunity induced by vaccination or prior infection and show resistance to therapeutic antibodies. Furthermore, the persistence of the virus in various anatomical sites is a suspected driver of Long COVID. Current treatments primarily focus on preventing viral entry or replication but do not specifically eliminate cells already harboring the infection. This study describes a novel "search-and-destroy" strategy using engineered Vesicular Stomatitis Virus (VSV) particles to address these gaps.

The VSV-ACE2 "Search-and-Destroy" Strategy

Researchers engineered VSV particles to display the human ACE2 receptor—the primary "doorway" the virus uses to enter cells—on their surface. By replacing the native VSV glycoprotein (G) with ACE2, they created a dual-action therapeutic tool:

  1. Decoy Neutralization: The ACE2-coated particles act as "sponges," binding to free-floating SARS-CoV-2 virions and preventing them from infecting host cells.
  2. Targeted Elimination: Infected cells express the SARS-CoV-2 Spike protein on their surface before releasing new virions. The VSV-ACE2 particles recognize these Spike-positive cells, infect them, and trigger rapid cell death (apoptosis), effectively shutting down the viral production line.
Figure 5: Overview of the VSV-ACE2 strategy, including the mechanism of action (a), in vitro validation across variants (b-f), and in vivo efficacy in hamsters (g-j).

Broad-Spectrum Efficacy and Variant Agnosticism

A key advantage of this approach is its resistance to viral evolution. Because the treatment targets the fundamental Spike-ACE2 interaction, any mutation that allows the virus to evade the VSV-ACE2 particles would likely also impair its ability to infect human cells. In vitro testing confirmed that VSV-ACE2 particles exclusively infected Spike-expressing cells and remained highly effective against multiple variants, including Alpha, Delta, and the highly evasive Omicron subvariants BA.2 and BA.5.

In Vivo Results in Hamster Models

The efficacy of the treatment was further validated in a Syrian gold hamster model infected with the SARS-CoV-2 Delta variant. Intranasal administration of VSV-ACE2 particles significantly improved clinical outcomes:

  • Viral Load Reduction: Viral RNA loads in the lungs and nasal passages were reduced by approximately five-fold compared to control groups.
  • Clinical Recovery: Treated animals exhibited significantly less weight loss (1.9% loss vs. 3.4% in the control group).
  • Mechanism Confirmation: Immunofluorescence microscopy of lung tissue provided direct evidence of the "search-and-destroy" mechanism, showing that VSV particles specifically localized to and infected cells expressing the SARS-CoV-2 Spike protein.
Figure 3: Immunofluorescence imaging of hamster lung tissue showing VSV-ACE2 particles (green) specifically targeting and infecting cells expressing the SARS-CoV-2 Spike protein (red).

Conclusion and Future Outlook

This study provides a robust proof-of-concept for using receptor-pseudotyped viruses to treat persistent and evolving viral infections. While the current research utilized non-replicating particles, the authors suggest that future work should explore recombinant, replication-competent VSV-ACE2. Such a "live" therapeutic could autonomously spread through infected tissues, hunting and eliminating viral reservoirs until the infection is cleared. However, transitioning to a replicating virus will require stringent safety evaluations to ensure the therapeutic does not cause unintended adverse effects.

Summary updated

Abstract

Effective vaccines and some antiviral agents against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), have been developed.Nonetheless, additional therapeutics are needed since emerging SARS-CoV-2 variants evade immunity induced by vaccination or previous infection and are resistant to therapeutic antibodies and fusion inhibitors. 1 In addition, many patients experience prolonged post-acute sequelae of SARS-CoV-2, also known as Long COVID. 2 One reason for this is the prolonged presence of SARS-CoV-2 in various anatomic sites for several months. 3In addition, impaired immune function due to advanced age, immunosuppressive therapy, autoimmune diseases, and comorbidities, such as diabetes or heart disease, as well as effective immune evasion of emerging SARS-CoV-2 variants may delay viral clearance. 4,5Thus, the elimination of SARS-CoV-2 infected cells is of great interest to prevent severe COVID-19 and to reduce the risk of long-term complications. 6However, none of the available antiviral agents target SARS-CoV-2-infected cells.Vesicular stomatitis virus (VSV) particles pseudo-typed with the SARS-CoV-2 Spike instead of the VSV-G glycoprotein are commonly used to study SARS-CoV-2 entry and neutralization.The primary receptor of SARS-CoV-2 is Angiotensin-converting enzyme 2 (ACE2), a single-pass type I membrane protein of ~805 amino acids. 7Here, we examined whether reversing this system, i.e. pseudo-typing VSV with ACE2, allows specific targeting and inhibition of both SARS-CoV-2 particles and infected cells.VSV replicates very fast and usually kills infected cells within less than a day by causing cytopathic effects and apoptosis.Thus, VSV is applied in oncolytic virus therapy to eliminate cancer cells. 8
BibTeX
@inproceedings{zech2023sars,
  author = {Fabian Zech and Stefanie Weber and Hanna Dietenberger and Linyun Zhang and Sabrina Noettger and Meta Volčič and Tim Bergner and Clarissa Read and Konstantin M. J. Sparrer and Thomas F.E. Barth and Frank Kirchhoff},
  title = {{SARS-CoV-2 inhibition and specific targeting of infected cells by VSV particles carrying the ACE2 receptor}},
  booktitle = {Signal},
  year = {2023},
  doi = {10.1038/s41392-023-01492-7},
}
Figure